Curis
Open
$0.39
Prev. Close
$0.39
High
$0.39
Low
$0.39
Market Snapshot
$15.19M
-0.7
-6.89
$10.91M
22
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Recently from Cashu
Curis Advances Emavusertib Trials Targeting Oncology Challenges Across Multiple Cancer Types
Curis, Inc. (Ticker: CRIS) is in the advanced stages of developing emavusertib, a promising therapeutic candidate that targets significant oncology challenges. The company highlights the ongoing Phase…
Curis Raises $80.8 Million for Emavusertib Development in Private Placement Financing
Curis Secures $80.8 Million in Private Placement to Advance Emavusertib Development Curis, Inc., a biotechnology company focused on innovative cancer therapies, successfully closes a private placement…
Curis Secures $80.8 Million to Advance Emavusertib Development and Strengthen Market Position
Curis Secures $80.8 Million to Propel Development of Emavusertib Curis, Inc., a biotechnology firm located in Lexington, Massachusetts, is making significant strides in its development efforts by anno…
Curis Secures $80.8 Million to Advance Emavusertib Development in Cancer Therapy
Curis Secures $80.8 Million Financing to Advance Emavusertib Development Curis, Inc., a biotechnology firm located in Lexington, Massachusetts, announces a significant private placement financing agre…